Promising combo targets Hard-to-Treat leukemia
NCT ID NCT04872790
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This early-phase study tests a new combination of drugs for adults with a specific type of leukemia (Ph+ ALL or MPAL) that is either newly diagnosed or has returned. The main goal is to find the safest dose of venetoclax when added to standard treatments like dasatinib, prednisone, and sometimes rituximab or blinatumomab. About 20 participants will be enrolled to monitor side effects and see how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED PHENOTYPE ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.